Patterns of spread of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by PET/CT 18F-FDG;Patrones de extensión de los tumores del estroma gastrointestinal (GIST) tratados con imatinib (Gleevec®) mediante PET/TC con 18F-FDG

Revista Espanola de Enfermedades Digestivas

Volumn 104, Issue 7, 2012, Pages 360-366

  Ferrusola, Eulalia Valls ^a   Garzón, Juan Ramón García ^a   López, Ana Ponce ^a   Peter, Marina Soler ^a   Cabero, Silvia Fuertes ^a   Solanes, Merce Moragas ^a   Gil, Eduard Riera ^a   Gasset, Ignasi Carrió ^a   Caballero, Francisco Lomeña ^a  

^a Anatomía patológica   (Spain)

Author keywords

GIST; Metastases

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; LIVER METASTASIS; LIVER RESECTION; MALE; METASTASIS; OBSERVATIONAL STUDY; PATIENT MONITORING; PERITONEUM METASTASIS; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; RECTUM CANCER; RECTUM METASTASIS; RETROSPECTIVE STUDY; SMALL INTESTINE CANCER; SMALL INTESTINE METASTASIS; STOMACH CANCER; STOMACH METASTASIS; TREATMENT RESPONSE; WHOLE BODY CT; WHOLE BODY PET; AGED; DRUG MONITORING; EVALUATION; GASTROINTESTINAL TUMOR; MIDDLE AGED; PATHOLOGY; SCINTISCANNING; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; DRUG MONITORING; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PYRIMIDINES; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864448732     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/s1130-01082012000700005     Document Type: Article

References (11)

1. Muñoz C, Sabah S, Navarro A, Planzer M, Silva C, Santander R. Tumores del estroma gastrointestinal (GIST): Revisión de la literatura. Gastr Latinoam 2006;17:43-51.
2. Stamatakos M, Douzinas E, Stefanaki C, Safioleas P, Polyzou E, Levidou G, et al. Gastrointestinal stromal tumor. World J Surg Oncol 2009;7:61.
3. Simó M, García JR, Soler M, Pérez G, López S, Lomeña FJ. Utilidad de la PET con FDG en el estudio de estadificación inicial, recurrencia y respuesta al tratamiento con imatinib (Glivec) en pacientes diagnosticados de un tumor del estroma gastrointestinal. Rev Esp Med Nucl 2006; 25:80-8.
4. Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003;226:527-32.
5. Wong CS, Chu YC, Khong PL. Unusual features of gastrointestinal stromal tumor on PET/CT and CT imaging. Clin Nucl Med 2011; 36:e1-7.
6. Igwilo OC, Byrne MP, Nguyen KD, Atkinson J. Malignant gastric stromal tumor: Unusual metastatic patterns. South Med J 2003;96:512-5.
7. Carreras Delgado JL, editor. Utilidad de la PET-TAC en oncología. Madrid: Arán Ediciones; 2010.
8. Nannini M, Biasco G, Di Scioscio V, Di Battista M, Zompatori M, Catena F, et al. Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (Case reports). Oncol Rep 2011;25:113-20.
9. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32:153-62.
10. Otomi Y, Otsuka H, Morita N, Terazawa K, Furutani K, Harada M, Nishitani H. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest 2010;57:270-4.
11. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 2008;13(Supl. 2):8-13.